Therapeutic potentials of fasudil in liver fibrosis

Yue Xi; Peng-Fei Xu

doi:10.3748/wjg.v27.i45.7859

Therapeutic potentials of fasudil in liver fibrosis

World J Gastroenterol. 2021 Dec 7;27(45):7859-7861. doi: 10.3748/wjg.v27.i45.7859.

Authors

Yue Xi¹, Peng-Fei Xu²

Affiliations

¹ Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, United States.
² Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, United States. pex9@pitt.edu.

Abstract

Fasudil has the potential to prevent liver fibrosis by activating natural killer cells and inhibiting the proliferation of hepatic stellate cells. Fasudil may be a promising clinical therapeutic drug for the prevention and treatment of liver fibrosis.

Keywords: Clinical therapeutic drug; Fasudil; Hepatic stellate cell; Liver fibrosis; Natural killer cell.

MeSH terms

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / therapeutic use
Hepatic Stellate Cells* / pathology
Humans
Killer Cells, Natural
Liver / pathology
Liver Cirrhosis* / drug therapy
Liver Cirrhosis* / pathology

Substances

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
fasudil